Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €11.70 EUR
Change Today +0.151 / 1.31%
Volume 0.0
KYX On Other Exchanges
Symbol
Exchange
KYX is not on other exchanges.
As of 6:07 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

keryx biopharmaceuticals (KYX) Snapshot

Open
€11.91
Previous Close
€11.55
Day High
€11.91
Day Low
€11.47
52 Week High
09/2/14 - €14.14
52 Week Low
05/9/14 - €8.48
Market Cap
1.2B
Average Volume 10 Days
558.9
EPS TTM
--
Shares Outstanding
103.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KERYX BIOPHARMACEUTICALS (KYX)

keryx biopharmaceuticals (KYX) Related Bloomberg News

View More Bloomberg News

keryx biopharmaceuticals (KYX) Related Businessweek News

No Related Businessweek News Found

keryx biopharmaceuticals (KYX) Details

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company also has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.

155 Employees
Last Reported Date: 02/27/15
Founded in 1997

keryx biopharmaceuticals (KYX) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $475.0K
Chief Financial Officer and Treasurer
Total Annual Compensation: $405.0K
Compensation as of Fiscal Year 2013.

keryx biopharmaceuticals (KYX) Key Developments

Keryx Biopharmaceuticals Inc. Appoints Greg Madison to its Board of Directors

Keryx Biopharmaceuticals Inc. announced the appointment of Mr. Greg Madison, the company's President and Chief Operating Officer and incoming Chief Executive Officer, to its Board of Directors, effective March 10, 2015. With the addition of Mr. Madison to Keryx's Board, the company has increased the size of its Board to 8 members. Mr. Madison joined Keryx in February 2014 and is currently the company's President and Chief Operating Officer, and will transition to the role of Chief Executive Officer by the end of May 2015. Mr. Madison has more than 20 years of experience in the US pharmaceutical industry.

Keryx Biopharmaceuticals Inc. Announces Publication of Auryxia™ (Ferric Citrate) Analysis in Journal of the American Society of Nephrology

Keryx Biopharmaceuticals Inc. announced the publication of Auryxia™ (ferric citrate) data and expert analyses in two peer-reviewed journals. An analysis of the effect of Auryxia on intravenous (IV) iron and erythropoiesis-stimulating agent (ESA) dosage and utilization was published in the Journal of the American Society of Nephrology (JASN). Auryxia was approved by the U.S. Food and Drug Administration in September 2014 for the control of serum phosphorus levels in chronic kidney disease (CKD) patients on dialysis. The publication in JASN, titled "Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD" was led by Kausik Umanath, MD, Division of Nephrology and Hypertension at Henry Ford Hospital. The analysis was based on the Phase 3 long-term safety and efficacy trial of Auryxia in dialysis-dependent CKD patients. The primary data from this study was published in 2014 in the Journal of the American Society of Nephrology. Separately, an expert analysis was also recently published online in Expert Review of Pharmacoeconomics & Outcomes Research. The review titled "Phosphorus Binding with Ferric Citrate Is Associated with Fewer Hospitalizations and Reduced Hospitalization Costs" was published online in Expert Review of Pharmacoeconomics & Outcomes Researchand was led by Roger A. Rodby, MD, Division of Nephrology, Rush University Medical Center. This post-hoc analysis was based on the Phase 3 long-term safety and efficacy trial of Auryxia in dialysis-dependent chronic kidney disease patients. About End Stage Renal Disease (ESRD) and Hyperphosphatemia End-stage renal disease (ESRD) represents the most severe stage of CKD, as many metabolic factors, such as iron and phosphorus, are out of balance. The majority of ESRD patients require chronic treatment with phosphate-binding agents to lower and maintain serum phosphorus at acceptable levels. In addition, iron can be severely depleted in dialysis patients and they therefore are often treated with intravenous iron and other medications. Approximately 450,000 ESRD patients require dialysis in the U.S., with the number projected to rise in the future. About Auryxia™ (ferric citrate) Auryxia™ (ferric citrate) was approved by the U.S. Food and Drug Administration on September 5, 2014 and is indicated in the U.S. for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The U.S. approval of Auryxia was based on data from the Company's Phase 3 registration program. In the Phase 3 clinical trials, Auryxia effectively reduced serum phosphorus levels to within the KDOQI guidelines range of 3.5 to 5.5 mg/dL. Auryxia binds with dietary phosphate in the GI tract, and forms non-absorbable complexes which are excreted. Auryxia has been shown to increase serum iron parameters including ferritin and transferrin saturation (TSAT), whereas these parameters remained relatively constant in patients treated with active control (Renvela® and/or Phoslo®). Iron absorption from Auryxia may lead to excessive elevations in iron stores. Accordingly, physicians should assess and monitor iron parameters before starting and while on Auryxia, and may need to decrease or discontinue IV iron for these patients. The most common adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, vomiting and constipation.

James Oliviero to Leave Keryx Biopharmaceuticals Inc. as Chief Financial Officer, Effective October 2015

On February 27, 2015, Keryx Biopharmaceuticals Inc. announced a planned consolidation of its finance and accounting function into its Boston office and that its Chief Financial Officer, James Oliviero, will be leaving Keryx by October 2015. Mr. Oliviero has been with Keryx for twelve years and has served as the Chief Financial Officer since 2009. The company has commenced a search for a new Chief Financial Officer who will be based in its Boston office. Mr. Oliviero will continue to manage the company's finance and accounting team during the remainder of his tenure and will assist in the transition of his duties to the new Chief Financial Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KYX:GR €11.70 EUR +0.151

KYX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KYX.
View Industry Companies
 

Industry Analysis

KYX

Industry Average

Valuation KYX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 108.0x
Price/Book 16.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 113.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KERYX BIOPHARMACEUTICALS, please visit www.keryx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.